MCID: HYP025
MIFTS: 49

Hyperphosphatemia

Categories: Genetic diseases, Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

MalaCards integrated aliases for Hyperphosphatemia:

Name: Hyperphosphatemia 12 30 56 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050459
MeSH 45 D054559
NCIt 51 C113750
SNOMED-CT 69 20165001
UMLS 74 C0085681

Summaries for Hyperphosphatemia

Disease Ontology : 12 A phosphorus metabolism disease characterized by hyperphosphatemia and abnormal deposits of phosphate and calcium in joints and soft tissues, results from abnomral phosphorus metabolism and has material basis in mutations in the FGF23, GALNT3 or KL gene.

MalaCards based summary : Hyperphosphatemia is related to tumoral calcinosis, hyperphosphatemic, familial, 1 and pseudohypoparathyroidism, type ib. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Ca, cAMP and Lipid Signaling. The drugs Calcium Carbonate and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and liver, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 77 Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial, 1 33.9 FGF23 GALNT3 KL
2 pseudohypoparathyroidism, type ib 32.2 GNAS PTH STX16
3 hypoparathyroidism, familial isolated 31.5 CASR GCM2 PTH
4 hyperostosis 30.9 FGF23 GALNT3 KL
5 familial tumoral calcinosis 30.6 FGF23 GALNT3 KL
6 calcinosis 30.5 FGF23 GALNT3 KL MGP
7 hypophosphatemia 30.5 FGF23 PTH SLC34A1
8 hypocalcemia, autosomal dominant 1 30.2 ALB CASR FGF23 GCM2 GNAS PTH
9 chronic kidney failure 29.9 ALB CASR FGF23 PTH VDR
10 hyperparathyroidism 29.8 CASR FGF23 GCM2 PTH VDR
11 hypoparathyroidism 29.7 CASR FGF23 GCM2 PTH
12 rickets 29.6 FGF23 PTH SLC34A1 VDR
13 kidney disease 29.5 ALB CASR FGF23 MGP PTH VDR
14 uremia 29.4 ALB CASR PTH VDR
15 bone disease 29.0 CASR FGF23 PTH RUNX2 VDR
16 calciphylaxis 28.9 ALB CASR FGF23 PTH VDR
17 osteoporosis 27.7 CASR FGF23 KL MGP PTH RUNX2
18 hyperphosphatemia, polyuria, and seizures 12.2
19 tumoral calcinosis, hyperphosphatemic, familial, 2 11.6
20 tumoral calcinosis, hyperphosphatemic, familial, 3 11.3
21 pseudohypoparathyroidism, type ia 11.0
22 pseudohypoparathyroidism, type ii 11.0
23 hypoparathyroidism-retardation-dysmorphism syndrome 11.0
24 hypoparathyroidism, x-linked 11.0
25 pseudohypoparathyroidism, type ic 11.0
26 leukemia 10.4
27 tracheal calcification 10.3 FGF23 KL
28 autosomal recessive hypophosphatemic rickets 10.3 FGF23 GALNT3
29 oncogenic osteomalacia 10.3 FGF23 PTH
30 hypophosphatemic rickets, autosomal dominant 10.3 FGF23 GALNT3
31 impaired renal function disease 10.3 FGF23 PTH
32 lymphocytic leukemia 10.3
33 hypothyroidism, congenital, nongoitrous, 1 10.3 GNAS STX16
34 chief cell adenoma 10.3 GCM2 PTH
35 connective tissue benign neoplasm 10.3 GNAS PTH
36 end stage renal failure 10.3
37 myeloma, multiple 10.2
38 leukemia, acute lymphoblastic 10.2
39 albright's hereditary osteodystrophy 10.2 GNAS STX16
40 secondary hyperparathyroidism 10.2
41 lactic acidosis 10.2
42 pseudopseudohypoparathyroidism 10.2 GNAS PTH STX16
43 pseudohypoparathyroidism 10.2 GNAS PTH STX16
44 metaphyseal chondrodysplasia, jansen type 10.1 FGF23 PTH
45 pulmonary alveolar microlithiasis 10.1 FGF23 PTH SLC34A1
46 arterial calcification of infancy 10.1 FGF23 MGP
47 osseous heteroplasia, progressive 10.1 GNAS RUNX2
48 metabolic acidosis 10.1
49 thyroid crisis 10.1 ALB PTH
50 glucocorticoid-induced osteoporosis 10.1 PTH RUNX2

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ALB CASR FGF23 GALNT3 GCM2 GNAS
2 growth/size/body region MP:0005378 10.22 CASR FGF23 GALNT3 GNAS KL MGP
3 cellular MP:0005384 10.19 ALB CASR GALNT3 GCM2 GNAS KL
4 endocrine/exocrine gland MP:0005379 10.19 ALB CASR FGF23 GALNT3 GCM2 GNAS
5 cardiovascular system MP:0005385 10.15 FGF23 GALNT3 GNAS KL MGP PTH
6 craniofacial MP:0005382 10.07 GALNT3 GCM2 GNAS KL PTH RUNX2
7 hematopoietic system MP:0005397 10.06 CASR FGF23 GALNT3 GNAS KL PTH
8 digestive/alimentary MP:0005381 10.05 ALB CASR FGF23 GALNT3 KL RUNX2
9 immune system MP:0005387 10.01 CASR FGF23 GALNT3 GNAS KL PTH
10 mortality/aging MP:0010768 10 ALB CASR FGF23 GCM2 GNAS KL
11 integument MP:0010771 9.91 CASR FGF23 GALNT3 GNAS KL RUNX2
12 limbs/digits/tail MP:0005371 9.87 FGF23 GALNT3 GNAS KL PTH RUNX2
13 muscle MP:0005369 9.81 ALB CASR GALNT3 GNAS KL MGP
14 renal/urinary system MP:0005367 9.65 ALB CASR FGF23 GALNT3 GCM2 GNAS
15 skeleton MP:0005390 9.4 CASR FGF23 GALNT3 GCM2 GNAS KL

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
2
Nicotinamide Approved, Investigational Phase 4,Phase 2,Phase 1 98-92-0 936
3
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68-04-2
4
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
5
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52757-95-6
6
Calcium acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-54-4
7
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Not Applicable 9002-64-6
8
Cinacalcet Approved Phase 4 226256-56-0 156419
9
Atorvastatin Approved Phase 4 134523-00-5 60823
10
Iron Approved, Experimental Phase 4,Phase 3,Phase 2 7439-89-6, 15438-31-0 27284 23925
11
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
12
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
13
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 59-67-6 938
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
16
Alfacalcidol Approved, Nutraceutical Phase 4,Not Applicable 41294-56-8 5282181
17
Calcitriol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 32222-06-3 5280453 134070
18
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 50-14-6 5280793
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
20
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
21
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
22
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
23 Lipid Regulating Agents Phase 4,Phase 2,Phase 1
24 Nicotinic Acids Phase 4,Phase 2,Phase 1
25 Antimetabolites Phase 4,Phase 2,Phase 1
26 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Vitamin B Complex Phase 4,Phase 2,Phase 1
31 Folate Phase 4,Phase 2,Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Vitamin B3 Phase 4,Phase 2,Phase 1
35 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Vasodilator Agents Phase 4,Phase 2,Phase 1
37 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hypolipidemic Agents Phase 4,Phase 2,Phase 1
41 Vitamin B9 Phase 4,Phase 2,Phase 1
42 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
43 Ferric Compounds Phase 4,Phase 3,Phase 2
44 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Citrate Phase 4,Phase 3,Phase 2,Phase 1
46 Hematinics Phase 4,Phase 3,Phase 2
47 Hydroxycholecalciferols Phase 4,Not Applicable
48 Vasoconstrictor Agents Phase 4,Phase 2,Not Applicable
49 Calciferol Phase 4,Phase 3,Phase 2,Not Applicable
50 Vitamin D2 Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 184)
# Name Status NCT ID Phase Drugs
1 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
3 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
4 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
5 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
6 Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease Completed NCT00160121 Phase 4 Lanthanum carbonate
7 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
8 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
9 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
10 Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients Completed NCT01427907 Phase 4 Calcium acetate oral solution (COS);Sevelamer carbonate
11 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
12 Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00091481 Phase 4 Zemplar
13 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
14 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
15 TOnicity of Perioperative Maintenance SoluTions Completed NCT03080831 Phase 4 NaCl 0.9% in Glucose 5% + 40mmol/L Potassium;Glucion 5%
16 Phophate Lowering Trial Recruiting NCT02209636 Phase 4 Lanthanum carbonate;placebo;Ascorbic Acid;Nitroglycerin
17 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Active, not recruiting NCT03079869 Phase 4 Ferric Citrate
18 Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Active, not recruiting NCT03256838 Phase 4 Ferric Citrate
19 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
20 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
21 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
22 Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 Terminated NCT00452478 Phase 4 Lanthanum carbonate
23 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
24 Vitamin D and Carboxy PTH Fragments in Coronary Calcification Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
25 Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction Unknown status NCT01357317 Phase 3 Phosphorus binder
26 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
27 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
28 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
29 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
30 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
31 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
32 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
33 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
34 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
35 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
36 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
37 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
38 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
39 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
40 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
41 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
42 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
43 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3 MCI-196;Placebo
44 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
45 A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Completed NCT01324128 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate;PA21-1 (1.25 g tablet containing 250 mg iron)
46 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
47 A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Completed NCT01464190 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate
48 Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study Completed NCT01578200 Phase 3 Lanthanum Carbonate;Calcium Carbonate
49 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3 ferric citrate
50 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets

Search NIH Clinical Center for Hyperphosphatemia

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

# Genetic test Affiliating Genes
1 Hyperphosphatemia 30

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

42
Kidney, Bone, Liver, Smooth Muscle, Heart, Myeloid, Endothelial

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 508)
# Title Authors Year
1
Combined effects of hyperphosphatemia and hyperglycemia on the calcification of cultured human aortic smooth muscle cells. ( 30651873 )
2019
2
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. ( 29617976 )
2019
3
Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks. ( 30087012 )
2019
4
Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Questions. ( 30291427 )
2019
5
Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Answers. ( 30291428 )
2019
6
A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia. ( 30664365 )
2019
7
Nano-lanthanum hydroxide, a novel phosphate binder, for treating hyperphosphatemia: A preclinical study. ( 30841470 )
2019
8
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. ( 30846557 )
2019
9
Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia. ( 30887097 )
2019
10
Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease. ( 30906759 )
2019
11
Hyperphosphatemia is associated with high mortality in severe burns. ( 29315336 )
2018
12
Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism. ( 29903718 )
2018
13
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. ( 28777915 )
2018
14
Surface-Engineered Blood Adsorption Device for Hyperphosphatemia Treatment. ( 28799951 )
2018
15
Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients. ( 28975589 )
2018
16
Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. ( 29295646 )
2018
17
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. ( 29340316 )
2018
18
Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease. ( 29486729 )
2018
19
Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients. ( 29561409 )
2018
20
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease. ( 29566839 )
2018
21
Prevention and treatment of hyperphosphatemia in chronic kidney disease. ( 29580635 )
2018
22
Patient education for hyperphosphatemia management: Improving outcomes while decreasing costs? ( 29629272 )
2018
23
Dietary Management of Hyperphosphatemia. ( 29655498 )
2018
24
A Decision Support Tool for Healthcare Professionals in the Management of Hyperphosphatemia in Hemodialysis. ( 29678073 )
2018
25
Current and potential treatment options for hyperphosphatemia. ( 29783873 )
2018
26
Blood pressure and heart rate variability are linked with hyperphosphatemia in chronic kidney disease patients. ( 29947550 )
2018
27
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. ( 29985725 )
2018
28
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease. ( 30022383 )
2018
29
Hyperphosphatemia Promotes Senescence of Myoblasts by Impairing Autophagy Through Ilk Overexpression, A Possible Mechanism Involved in Sarcopenia. ( 30271655 )
2018
30
Treatment of hyperphosphatemia based on specific interactions between phosphorus and Zr(iv) active centers of nano-MOFs. ( 30319748 )
2018
31
Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders. ( 30327732 )
2018
32
Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease. ( 30588573 )
2018
33
Hyperphosphatemia is not significantly associated with increased all-cause mortality in Korean hemodialysis patients. ( 30619699 )
2018
34
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. ( 28533541 )
2017
35
Uremic Tumoral Calcinosis Resolved by Improvements in Hyperphosphatemia. ( 28626193 )
2017
36
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( 27933339 )
2017
37
Erratum to: Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. ( 27832343 )
2017
38
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. ( 27837149 )
2017
39
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. ( 28078600 )
2017
40
Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. ( 28182142 )
2017
41
Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients. ( 28218647 )
2017
42
Educational nursing intervention to reduce the hyperphosphatemia in patients on hemodialysis. ( 28226039 )
2017
43
Antibody-mediated inhibition of EGFR reduces phosphate excretion and induces hyperphosphatemia and mild hypomagnesemia in mice. ( 28292888 )
2017
44
Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. ( 28321403 )
2017
45
Hyperphosphatemia, a Cause of High Anion Gap Metabolic Acidosis: Report of a Case and Review of the Literature. ( 28450695 )
2017
46
Effect of Vitamin D Supplementation on Delayed Hyperphosphatemia in Pediatric Acute Lymphoblastic Leukemia Patients During Induction Chemotherapy. ( 28469534 )
2017
47
Activation of the Nrf2-ARE Signaling Pathway Prevents Hyperphosphatemia-Induced Vascular Calcification by Inducing Autophagy in Renal Vascular Smooth Muscle Cells. ( 28513870 )
2017
48
Analysis of Hypo- and Hyperphosphatemia in an Intensive Care Unit Cohort. ( 28525508 )
2017
49
Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode". ( 28528515 )
2017
50
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. ( 28550969 )
2017

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 8.92 CASR GNAS KL SLC34A1

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.78 ALB FGF23 SLC34A1
2 skeletal system development GO:0001501 9.67 GNAS PTH RUNX2 VDR
3 fibroblast growth factor receptor signaling pathway GO:0008543 9.65 FGF23 GALNT3 KL
4 cellular calcium ion homeostasis GO:0006874 9.62 CASR GCM2 PTH VDR
5 embryonic cranial skeleton morphogenesis GO:0048701 9.6 GNAS RUNX2
6 positive regulation of bone mineralization GO:0030501 9.59 KL PTH
7 response to cadmium ion GO:0046686 9.58 PTH SLC34A1
8 endochondral ossification GO:0001958 9.58 GNAS RUNX2
9 regulation of bone mineralization GO:0030500 9.57 FGF23 MGP
10 response to lead ion GO:0010288 9.56 PTH SLC34A1
11 ossification GO:0001503 9.56 CASR MGP RUNX2 SLC34A1
12 energy reserve metabolic process GO:0006112 9.55 GNAS KL
13 response to magnesium ion GO:0032026 9.54 FGF23 SLC34A1
14 vitamin D metabolic process GO:0042359 9.52 FGF23 VDR
15 cellular response to vitamin D GO:0071305 9.51 CASR FGF23
16 cellular response to parathyroid hormone stimulus GO:0071374 9.49 FGF23 SLC34A1
17 response to fibroblast growth factor GO:0071774 9.46 CASR PTH
18 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.43 FGF23 KL
19 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.4 FGF23 VDR
20 cellular phosphate ion homeostasis GO:0030643 9.33 FGF23 GCM2 SLC34A1
21 phosphate ion homeostasis GO:0055062 9.13 FGF23 PTH SLC34A1
22 response to parathyroid hormone GO:0071107 8.8 GNAS PTH SLC34A1

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 8.96 FGF23 KL
2 vitamin D binding GO:0005499 8.62 KL VDR

Sources for Hyperphosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....